CD24 cells from hierarchically organized ovarian cancer are enriched in cancer stem cells

Cancer stem cells (CSCs) have been identified in solid tumors and cancer cell lines. In this study, we isolated a series of cancer cell clones, which were heterogeneous in growth rate, cell cycle distribution and expression profile of genes and proteins, from ovarian tumor specimens of a patient and...

Full description

Saved in:
Bibliographic Details
Published inOncogene Vol. 29; no. 18; pp. 2672 - 2680
Main Authors Gao, M-Q, Choi, Y-P, Kang, S, Youn, J H, Cho, N-H
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 06.05.2010
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Cancer stem cells (CSCs) have been identified in solid tumors and cancer cell lines. In this study, we isolated a series of cancer cell clones, which were heterogeneous in growth rate, cell cycle distribution and expression profile of genes and proteins, from ovarian tumor specimens of a patient and identified a sub-population enriched for ovarian CSCs defined by CD24 phenotype. Experiments in vitro demonstrated CD24 + sub-population possessed stem cell-like characteristics of remaining quiescence and more chemoresistant compared with CD24 − fraction, as well as a specific capacity for self-renewal and differentiation. In addition, injection of 5 × 10 3 CD24 + cells was able to form tumor xenografts in nude mice, whereas equal number of CD24 − cells remained nontumorigenic. We also found that CD24 + cells expressed higher mRNA levels of some ‘stemness’ genes, including Nestin, β-catenin, Bmi-1, Oct4, Oct3/4, Notch1 and Notch4 which were involved in modulating many functions of stem cells, and lower E-cadherin mRNA level than CD24 − cells. Altogether, these observations suggest human ovarian tumor cells are organized as a hierarchy and CD24 demarcates an ovarian cancer-initiating cell population. These findings will have important clinical applications for developing effective therapeutic strategies to treat ovarian cancer.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0950-9232
1476-5594
DOI:10.1038/onc.2010.35